CLNN Clene Inc
2,755
$0.40
$0.0188
(4.49%)
| Watchers | 2,755 |
| 52-Wk Low | $0.3576 |
| 52-Wk High | $1.99 |
| Market Cap | $53.78M |
| Volume (M) | 359,169.00 |
| 52-Wk High | $1.99 |
| 52-Wk Low | $0.3576 |
Clene Inc. (NASDAQ:CLNN) Receives Average Rating of "Buy" from BrokeragesZolmax • 23 days ago
Clene Inc. (NASDAQ:CLNN Get Free Report) has received a consensus rating of Buy from the six brokerages that are currently covering the stock, Marketbeat Ratings reports. Six...
Share to Feed
Clene Inc. (NASDAQ:CLNN Free Report) Equities researchers at HC Wainwright reduced their FY2023 earnings per share estimates for shares of Clene in a note issued to investors on...
Clene Inc. (NASDAQ:CLNN Get Free Report)s share price was down 3.6% during trading on Thursday . The stock traded as low as $0.39 and last traded at $0.40. Approximately 147,555 shares...
Reported statistically significant improved survival benefit of 19.3 months and significantly delayed clinical worsening in patients treated with CNM-Au8 in the RESCUE ALS open-label extension...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Funding to Support Research and Expanded Access of Investigational Drug in ALSSALT LAKE CITY, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene...
Prolonged life with 49% decreased risk of death for participants in the HEALEY ALS Platform Trial treated with CNM-Au8 30mg compared to PRO-ACT matched placebo over long-term follow-up...
SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene ) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage...
Clene Inc. (NASDAQ:CLNN Get Free Report) saw a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 410,400 shares, a decline of...
SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to ...